Thrombocytosis as a Marker for Postoperative Complications in Colorectal Surgery

M. Mohamud, L. Osborne, H. G. Jones, A. Ahmed, J. Beynon, D. A. Harris, M. Evans, M. Davies, U. Khot, and T. V. Chandrasekaran

Department of Surgery, Morriston Hospital, Heol Maes Eglwys, Morriston, Swansea SA6 6NL, UK

Correspondence should be addressed to M. Mohamud; mohamedm@doctors.org.uk

Received 8 March 2018; Accepted 8 August 2018; Published 26 August 2018

Academic Editor: Nicola Silvestris

Copyright © 2018 M. Mohamud et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Blood platelet measurement is a widely available and inexpensive test that is performed routinely. Platelets are thought to act by inducing inflammation and play a role in clotting and antimicrobial defence. A postoperative rise in the platelet count (thrombocytosis) is often dismissed as an incidental finding, but there is growing evidence to suggest that it may act as an indicator to underlying pathology. It correlates with significant pyogenic infections as well as multiple malignancies. In addition to this, recent research indicates that thrombocytosis may be a useful prognostic indicator for postoperative outcomes in patients with malignancies. In patients undergoing surgery for gastric cancer, a combination of platelet count and neutrophil-to-lymphocyte (NLR) ratio collected preoperatively was shown to correlate with postoperative survival.

Objective. To evaluate whether there is a positive correlation between pre- and postoperative thrombocytosis and the risk of complications following colorectal surgery.

Methods. This was a retrospective observational study based in Morriston Hospital, Swansea. Patients undergoing elective colorectal surgery for an 18-month period between 2014 and 2016 were included. Data on patient demographics, pre- and postoperative platelet count, the first date at which the highest platelet count was recorded, length of stay, type of operation, and postoperative complications using the Clavien-Dindo classification was obtained from the theatre booking software (TOMS) and Welsh Clinical Portal. Pearson’s chi-square test was used for the analysis of the categorical variables.

Results. Of the 201 patients studied, 75 (37%) had postoperative thrombocytosis (platelets ≥ 500 × 10^9/L, range 501–1136), 120 (59%) had postoperative normocytosis (platelets < 500 × 10^9/L, range 107–499), and 6 (2.9%) patients were excluded due to insufficient data. Peak platelet level was seen at a median of 8 days postoperatively but ranged from days 1 to 49. In patients with thrombocytosis, the mean time to peak platelet count was 9.5 days and ranged 1 to 49 days. 101/195 (52%) patients had a Clavien-Dindo III/V postoperative complication: 63% patients with postoperative normocytosis and 24% with postoperative thrombocytosis. In the thrombocytosis group, 16/75 (21%) were found to have postoperative pelvic collections compared to 1/120 (0.8%) of the normocytic patients. The total percentage of medical complications (44% versus 20%, p = 0.006) and surgical complications (64% versus 15.8%, p = 0.0001) was higher in the thrombocytosis group compared to the normocytosis group. Conclusion. In this retrospective study, thrombocytosis was shown to have a positive correlation with postoperative medical and surgical complications. An elevated platelet count in the postoperative period should alert the clinician to a developing complication. We recommend that further studies with a larger sample size would test the specific associations with individual complications.

1. Introduction

Platelet count is a routinely performed blood test both before and after major surgery as part of the full (or complete) blood count. The finding of an elevated platelet count has little significance attached in day to day practice with clinicians placing more emphasis on other inflammatory markers such as the total white blood cell count, neutrophil count, and C-reactive protein. Platelets are thought to act by inducing inflammation and in doing so play a role in the
body’s antimicrobial defence [1] and may be implicated in the postoperative inflammatory response.

There is growing evidence to suggest that an increased platelet count may act as an indicator to underlying pathology [2, 3]. Thrombocytosis (high platelet count > 500 × 10⁹/L) is correlated with significant pyogenic infections such as empyema and abscess formation as well as acting as a possible precursor to soft tissue infections [4]. In addition, thrombocytosis is commonly seen in malignancy [5] and its use as a marker for predicting prognosis in rectal cancer [6], gynaecological malignancies [7–10], renal cell carcinomas [11], breast cancer [12], oesophageal cancer [13], gastric cancer [14], and lung cancer [15] is well documented.

Several papers have shown that thrombocytosis is a useful prognostic indicator for postoperative outcomes in patients with malignancy. In patients undergoing surgery for gastric cancer, a combination of platelet count and neutrophil to lymphocyte ratio (NLR) collected preoperatively was shown to correlate with postoperative survival [16]. Another study looked at postoperative platelet increase and its correlation to outcome in patients undergoing urological surgeries including radical cystectomy, percutaneous nephrolithotripsy, and nephrectomy [17]. In this study, there was a significantly higher rate of postoperative complications in patients who developed thrombocytosis after surgery compared to those who did not. There is little previously published about the implication of thrombocytosis after colorectal surgery.

2. Aim

The aim of this study was to evaluate whether there is a positive correlation between thrombocytosis and the development of complications after colorectal surgery.

3. Method

The study was based in the colorectal department at Morriston Hospital, a large secondary care university teaching hospital in Swansea, UK. We identified all patients who underwent elective colorectal surgery for an 18-month period between 2014 and 2016 from the national cancer registry (CANISC). Demographic details and operations performed were retrieved from the theatre booking software (TOMS database) to include management of complications. The variables assessed and recorded were pre- and postoperative platelet count, the first date at which the highest platelet count was recorded postoperatively, length of stay, type of operation, and complications using the Clavien-Dindo classification. We collected the information from the Welsh Clinical Portal (test result software) and the Synapse radiology portal. Patient case records were used to retrieve missing data. All the information gathered was stored in a password-protected spreadsheet and accessed from hospital computers. For statistical associations between categories of platelet count and individual complications, the Pearson’s chi-square test was used. Statistical significance was assumed at the 5% level.

4. Results

Of the 201 patients studied, 75 (37%) had postoperative thrombocytosis (platelets ≥ 500 × 10⁹/L, range 501–1136), 4 (1.9%) of which had platelet count ≥ 1000 × 10⁹/L, 120 (59%) had postoperative normocytosis (platelets < 500 × 10⁹/L, range 107–499), and 6 (2.9%) patients were excluded due to insufficient retrievable data. 191 of the 201 patients studied had normal platelet count preoperatively.

Peak platelet level was seen at a median of 8 days postoperatively but ranged from 1 to 49 days. In patients with thrombocytosis, the mean time to peak platelet count was 9.5 days and range 1 to 49 days.

Out of the 195 patients included into this study, 123 (63.1%) had complications postoperatively while 72 (36.9%) did not. In the normocytosis group, 76/120 (63.3%) had no recorded complications compared to 18/75 (24%) in patients with thrombocytosis.

Complications were categorised into medical complications, surgical complications, and death. Medical complications included atelectasis, pleural effusion, lower respiratory tract infection, consolidation, pulmonary embolism, and deep vein thrombosis. 54/195 (27.6%) of patients in the study group had medical complications. However, 21/120 (17.5%) of the normocytosis group had a medical complication compared to 33/75 (44%) of patients who had thrombocytosis. Of the 44% of patients with thrombocytosis who had medical complications, 12% of these had consolidation. However, only 2.5% of patients with normocytosis had consolidation in their postoperative course as shown in Table 1.

Surgical complications categorised in this study were ileus, small bowel obstruction, collection, anastomotic leak, perforations, and hernia. Overall, 30.7% of patients studied had a surgical complication. This percentage was higher in patients with thrombocytosis at 56% and lower in the normocytosis group at 15%. Of patients with thrombocytosis, 21% had a postoperative collection compared to 0.85% of patients with normocytosis. As well as this, the percentage of anastomotic leaks (12%) and perforations (2.6%) was higher in patients in the thrombocytosis group compared to patients in the normocytosis group where there were no recorded cases of perforations or anastomotic leaks.

The percentage of patients who died in each group was similar, with a mortality of 17.4% among all patients studied. This was slightly lower for the normocytosis group (16.6%) compared to the thrombocytosis group (18.6%).

When the Clavien-Dindo classification was used to classify complications, the normocytosis group was more likely to have grade I complications at 68% than the thrombocytosis group (30%) as shown in Table 2. However, patients with thrombocytosis were more likely to have grade II and grade III complications at 28% and 22.6%, respectively, compared to patients with normocytosis who had grade II (9.1%) and grade III (4.1%) complications.

101/195 (52%) patients had a Clavien-Dindo III/V postoperative complication; 63% of patients with postoperative normocytosis and 24% with postoperative thrombocytosis. In the thrombocytosis group, 16/75 (21%) were found to have postoperative pelvic collections compared to 1/120
The total percentage of medical complications (44% versus 20%, \( p = 0.006 \)) and surgical complications (64% versus 15.8%, \( p = 0.0001 \)) was higher in the thrombocytosis group compared to the normocytosis group.

### 5. Discussion and Conclusion

In this novel study, thrombocytosis was shown to have a positive correlation with postoperative medical and surgical complications following colorectal cancer surgery.

In the literature, platelets are thought to be an acute-phase reactant which increase in response to systemic insults such as inflammation, infections, neoplasms, and bleeding conditions [18–20]. This is what is termed as reactive or secondary thrombocytosis, and it is a benign state of thrombocytosis. Primary thrombocytosis (also known as essential thrombocytosis) is an unregulated abnormal production of platelets originating in the bone marrow. In normal states, thrombopoiesis (platelet production) is regulated by the hormone thrombopoietin secreted from the liver and kidneys [19–21].

The pathophysiology behind secondary thrombocytosis (reactive thrombocytosis) which we are concerned with in this study is thought to be as a result of increased levels of proinflammatory cytokines, such as interleukins (IL-1, IL-6, and IL-11) as seen in inflammatory, infective, and malignant states [22–25]. The increase in these proinflammatory substances is thought to lead to tissue damage. The nutrient-rich oedema can also act as the perfect culture medium for microorganisms to thrive which lead to further tissue destruction [26].

There is growing evidence to suggest that thrombocytosis states may act as an indicator to underlying pathological states, for example, septic and thromboembolic events [17]. An elevated platelet count should not merely be dismissed as a random occurrence in the postoperative period but should alert the duty clinician to a developing complication. They should actively seek out the cause through thorough history taking and clinical examination, and if indicated consider an urgent CT scan of the abdomen and pelvis [22–25].

The platelet count is an inexpensive and routinely collected proinflammatory marker to monitor for inflammatory and infective complications after surgery. We recommend that further studies with a larger sample size would test the specific associations with individual complications and try to define an absolute platelet level associated with complications.

### Table 1: Breakdown of complications.

| Medical complications | n   | %   | Medical complications | n   | %   | p value |
|-----------------------|-----|-----|-----------------------|-----|-----|---------|
| Atelectasis           | 9   | 12.0| Atelectasis           | 8   | 6.6 | 0.25    |
| Consolidation         | 9   | 12.0| Consolidation         | 3   | 2.5 | 0.01    |
| Effusion              | 8   | 10.6| Effusion              | 4   | 3.3 | 0.06    |
| PE                    | 6   | 8.0 | PE                    | 3   | 2.5 | 0.09    |
| LRTI                  | 1   | 1.3 | LRTI                  | 3   | 2.5 | 1.00    |

| Surgical complications | n   | %   | Surgical complications | n   | %   |
|------------------------|-----|-----|------------------------|-----|-----|
| Perforation            | 2   | 2.6 | Perforation            | 0   | 0.0 |
| Leak                   | 9   | 12.0| Leak                   | 0   | 0.0 |
| Small bowel obstruction| 1   | 1.3 | Small bowel obstruction| 2   | 1.6 |
| Collection             | 16  | 21.3| Collection             | 1   | 0.8 |
| Ileus                  | 2   | 2.6 | Ileus                  | 0   | 0.0 |
| Abscess                | 1   | 1.3 | Abscess                | 1   | 0.8 |
| Hernia                 | 5   | 6.6 | Hernia                 | 4   | 3.3 |

No significant difference was found between platelet count and the development of a Clavien-Dindo IV/V complication (\( p = 0.44 \)).

### Table 2: Complication rate according to Clavien-Dindo classification.

| Clavien-Dindo class   | n   | %   |
|-----------------------|-----|-----|
| Patients with platelets \( \geq 500 \times 10^9/L \) |
| I                     | 23  | 30.6|
| II                    | 21  | 28.0|
| III                   | 17  | 22.6|
| IV                    | 4   | 1.3 |
| V                     | 14  | 18.6|
| Patients with platelets \( < 500 \times 10^9/L \) |
| I                     | 82  | 68.3|
| II                    | 11  | 9.1 |
| III                   | 5   | 4.1 |
| IV                    | 1   | 0.8 |
| V                     | 20  | 16.6|

(0.8%) of the normocytic patients. The total percentage of medical complications (44% versus 20%, \( p = 0.006 \)) and surgical complications (64% versus 15.8%, \( p = 0.0001 \)) was higher in the thrombocytosis group compared to the normocytosis group.
Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure

Earlier version of this work was presented as an abstract at the Welsh Surgical Society meeting (24th Nov 2017) and a poster presentation at Association of Surgeons in Training (ASiT) International Conference in Edinburgh (April 2018) (Abstract Publication: Thrombocytosis as a marker for post-operative complications in colorectal surgery, International Journal of Surgery (IJS), volume 55, supplement 1, July 2018, pages S70-S71).

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Professor Dean A. Harris was responsible for the conception of the study. Other authors collected and analyzed the data and wrote the paper with M. Mohamud. All authors reviewed and approved the manuscript.

References

[1] M. H. F. Klinger and W. Jelkmann, “Review: role of blood platelets in infection and inflammation,” Journal of Interferon & Cytokine Research, vol. 22, no. 9, pp. 913–922, 2002.

[2] D. H. Buss, A. W. Cashell, M. L. O’Connor, F. Richards II, and L. D. Case, “Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases,” The American Journal of Medicine, vol. 96, no. 3, pp. 247–253, 1994.

[3] M. Griesshammer, M. Bangerter, T. Sauer, R. Wenaus, L. Bergmann, and H. Heimpel, “Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count,” Journal of Internal Medicine, vol. 245, no. 3, pp. 295–300, 1999.

[4] J. Z. Tchebiner, A. Nutman, B. Bourgi et al., “Diagnostic and prognostic value of thrombocytosis in admitted medical patients,” The American Journal of the Medical Sciences, vol. 342, no. 5, pp. 395–401, 2011.

[5] L. Riess, “Zur pathologische Anatomie des Blut,” JAMA, vol. 211, pp. 1852-1853, 1970, Physiol Wissensch Med 1872; 39: 237–49.

[6] A. Cravioto-Villanueva, P. Luna-Perez, M. Gutierrez-de la Barrera et al., “Thrombocytosis as a predictor of postoperative survival in patients with rectal cancer,” Archives of Medical Research, vol. 43, no. 4, pp. 305–311, 2012.

[7] G. C. Rodriguez, D. L. Clarke-Pearson, J. T. Soper, A. Berchuck, I. Synan, and R. K. Dodge, “The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer,” Obstetrics and Gynecology, vol. 83, no. 3, pp. 445–448, 1994.

[8] E. Hernandez, K. A. Donohue, L. L. Anderson, P. B. Heller, and F. B. Stehman, “The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 78, no. 2, pp. 137–142, 2000.

[9] A. G. Zeimet, C. Marth, E. Müller-Holzner, G. Daxenbichler, and O. Dapunt, “Significance of thrombocytosis in patients with epithelial ovarian cancer,” American Journal of Obstetrics & Gynecology, vol. 170, no. 2, pp. 549–554, 1994.

[10] C. Gorelick, V. Andikyan, M. Mack, Y. C. Lee, and O. Abulafia, “Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an inner-city population,” International Journal of Gynecological Cancer, vol. 19, no. 8, pp. 1384–1389, 2009.

[11] N. P. Symbas, M. F. Townsend, R. el-Galley, T. E. Keane, S. D. Graham, and J. A. Petros, “Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma,” BJU International, vol. 86, no. 3, pp. 203–207, 2000.

[12] S. Taucher, A. Salat, M. Gnant et al., “Impact of pretreatment thrombocytosis on survival in primary breast cancer,” Thrombosis and Haemostasis, vol. 89, no. 6, pp. 1098–1106, 2003.

[13] H. Shimada, G. Oohira, S. Okazumi et al., “Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma,” Journal of the American College of Surgeons, vol. 198, no. 5, pp. 737–741, 2004.

[14] M. Ikeda, H. Furukawa, H. Imamura et al., “Poor prognosis associated with thrombocytosis in patients with gastric cancer,” Annals of Surgical Oncology, vol. 9, no. 3, pp. 287–291, 2002.

[15] T. Encan and E. Hannisdal, “Blood analyses as prognostic factors in primary lung cancer,” Acta Oncologica, vol. 29, no. 2, pp. 151–154, 1990.

[16] M. Ishizuka, Y. Oyama, A. Abe, and K. Kubota, “Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients undergoing surgery for gastric cancer,” Journal of Surgical Oncology, vol. 110, no. 8, pp. 935–941, 2014.

[17] O. N. Gofrit, A. Shapiro, D. Rund et al., “Postoperative thrombocytosis as a marker for complications after urologic surgery,” Scandinavian Journal of Urology and Nephrology, vol. 40, no. 2, pp. 161–165, 2006.

[18] A. J. Vora and J. S. Lilleyman, “Secondary thrombocytosis,” Archives of Disease in Childhood, vol. 68, no. 1, pp. 88–90, 1993.

[19] P. Chiarello, M. Magnolia, M. Rubinio, S. A. Liguori, and R. Miniero, “Thrombocytosis in children,” Minerva Pediatrica, vol. 63, no. 6, pp. 507–513, 2011.

[20] A. Tefferi and T. Barbi, “Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management,” American Journal of Hematology, vol. 92, no. 1, pp. 94–108, 2017.

[21] K. Wille, P. Sadjadian, and M. Griesshammer, “Thrombocyto- sis and thrombocytopenia – background and clinical relevance,” DMW - Deutsche Medizinische Wochenschrift, vol. 142, no. 23, pp. 1732–1743, 2017.

[22] A. Tefferi, T. C. Ho, G. J. Ahmann, J. A. Katzmann, and P. R. Greipp, “Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis,” The American Journal of Medicine, vol. 97, no. 4, pp. 374–378, 1994.

[23] J. Kuti and H. Wadenvik, “Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis,” Leukemia & Lymphoma, vol. 22, Supplement 1, pp. 41–45, 1996.
[24] M. Araneda, V. Krishnan, K. Hall, J. Kalbfleisch, G. Krishnaswamy, and K. Krishnan, “Reactive and clonal thrombocytosis: proinflammatory and hematopoietic cytokines and acute phase proteins,” *Southern Medical Journal*, vol. 94, no. 4, pp. 417–420, 2001.

[25] K. Haidopoulou, M. Goutaki, M. Lemonaki, M. Kavga, and A. Papa, “Reactive thrombocytosis in children with viral respiratory tract infections,” *Minerva Pediatrica*, vol. 63, no. 4, pp. 257–262, 2011.

[26] S. C. Cotran, C. Kumar, T. Collins, and W. B. Robbins, *Robbins Pathologic Basis of Disease*, W. B Saunders Company, Philadelphia, PA, USA, 1998.